MedTrace Logo

Figitumumab Combined With Pegvisomant For Advanced Solid Tumors

NCT00976508 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2013-12-13

Study results available
· View outcomes & findings →

Summary

This is a Phase 1 study investigating the safety and tolerability of Figitumumab plus Pegvisomant for treatment of advanced solid tumors.

Conditions

  • Colorectal Neoplasms
  • Lung Neoplasms
  • Breast Neoplasms
  • Prostatic Neoplasms
  • Sarcoma

Interventions

DRUG

figitumumab

IGF-1R antibody, 20 mg/kg, IV every 3 weeks for up to 1 year

DRUG

pegvisomant

growth hormone antagonist, 10, 20 or 30 mg per day via subcutaneous injection for up to 1 year

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2011-09-30
Completion
2012-10-31

Countries

  • United States
  • Canada
  • Finland
  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00976508 on ClinicalTrials.gov